--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product--  --Seventh Addition to Lifecore&#39;s Late-Stage Pipeline in Seven Months--  CHASKA, Minn., June  15, 2026  (GLOBE

LFCR

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

Lifecore secures seventh late-stage agreement in seven months

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product--  --Seventh Addition to Lifecore&amp;#39;s Late-Stage Pipeline in Seven Months--  CHASKA, Minn., June  15, 2026  (GLOBE</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Lifecore Biomedical announced a new tech transfer agreement with a global pharmaceutical company to support the commercial production of an injectable suspension for neurological disorders. This marks Lifecore&#039;s seventh late-stage program win in seven months, underscoring strong momentum and demand for high-viscosity, complex injectable manufacturing in the U.S. The development could improve revenue visibility and backlog while expanding Lifecore’s partner ecosystem.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Lifecore signs new tech transfer deal for injectable neurology product.</li><li>Seventh late-stage program win in seven months signals momentum.</li><li>Deal underscores rising demand for high-viscosity injectable manufacturing in the U.S.</li><li>No financial terms disclosed; potential near-term revenue impact remains uncertain.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Lifecore Biomedical, Inc. (LFCR)</strong>: Announced new global pharma tech transfer agreement; potential revenue backlog growth.</li><li><strong>Global pharmaceutical company (unnamed) (N/A)</strong>: Partner in tech transfer for commercial injectable product; terms undisclosed.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The press release highlights a customer win and pipeline expansion, which can improve visibility into future revenue and potential backlog growth for Lifecore.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Seventh late-stage contract win in seven months signals backlog growth.</li><li>Demand for high-viscosity injectable manufacturing boosts Lifecore&#039;s premium capabilities.</li><li>Financial terms are undisclosed; near-term revenue impact remains uncertain.</li><li>Potential attraction of additional large customers could expand U.S. manufacturing footprint.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date: June 15, 2026.</li><li>Lifecore to perform tech transfer for commercial production of an injectable suspension for neurological disorders.</li><li>Seventh late-stage program win in seven months.</li><li>Lifecore is a fully integrated CDMO with expertise in sterile injectables and hyaluronic acid.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish for LFCR in 1–3 quarters as backlog and revenue visibility rise.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="center">--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product--</p>  <p align="center">--Seventh Addition to Lifecore's Late-Stage Pipeline in Seven Months--</p>  <p align="justify">CHASKA, Minn., June  15, 2026  (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/LFCR">LFCR</a>) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced it has signed a new agreement with a global pharmaceutical company. Under the terms of the agreement, Lifecore will perform technical transfer services to support the commercial production of an injectable suspension product for neurological disorders.   </p>  <p align="justify">"With this significant new customer win, we have secured our seventh agreement for a late-stage program within the last seven months, reflecting how our focused business development efforts have created strong momentum and results for continued portfolio growth," said Paul Josephs, chief executive officer of Lifecore. "Being selected to produce this higher-viscosity suspension formulation demonstrates confidence in Lifecore's technical know-how and exceptional quality track record.</p>  <p align="justify">"This opportunity also highlights the increasing demand for specialized manufacturing expertise to produce high-viscosity and other complex pharmaceutical products. Lifecore's unique capabilities position us as a valuable partner, able to address the diverse needs of multinational pharmaceutical companies seeking to leverage manufacturing operations in the U.S."</p>  <p align="justify"><strong>About Lifecore Biomedical </strong></p>  <p align="justify">Lifecore Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/LFCR">LFCR</a>) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore's website at <a href="https://www.globenewswire.com/Tracker?data=mjcDzFMY89XDUPIHyWzj1g6Itj-3ExddkysTfXm77y_Zvk5g9UuCpxUSGDXBvpX8f6-ak6OuQP0uzY4uJvdjGs1FyRlD5kSgZ3wTLWUSR8g=" rel="nofollow" target="_blank">www.lifecore.com</a>.</p>  <p align="justify"><strong>Important Cautions Regarding Forward-Looking Statements </strong></p>  <p align="justify">This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as "anticipate", "estimate", "expect", "project", "aim," "designed to," "plan", "intend", "believe", "may", "might", "will", "should", "can have", "likely" and similar expressions are used to identify forward-looking statements. In addition, all statements regarding our future financial and operating performance and strategy, including our strong momentum and results for continued portfolio growth; the increasing demand for specialized manufacturing expertise to produce high-viscosity and other complex pharmaceutical products; and our position as a valuable partner, able to address the diverse needs of multinational pharmaceutical companies seeking to leverage manufacturing operations in the U.S., are forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors as, among others, the timing and amount of future expenses, revenue, net income (loss), Adjusted EBITDA, cash flow and capital requirements, and timing and availability of and the need for additional financing; our ability to maintain or expand our relationships with our current customers, including the impact of changes in consumer demand for the products we manufacture for our customers; our ability to grow and diversify our business with new customers, including the potential loss of development customers if they do not receive required funding or regulatory approvals or for other reasons; our ability to comply with covenants under our credit agreements and to pay required interest and principal payments when due; our ability to fund any redemptions of shares of the outstanding Series A Convertible Preferred Stock if requested by holders in accordance with their terms; our ability to raise additional capital for ongoing needs, including through equity financing, debt financing, collaborations, strategic alliances or licensing arrangements; the impact of macroeconomic events or circumstances on our operations and financial performance, including inflation, tariffs, interest rates, social unrest and global instability; the performance of our third-party suppliers; pharmaceutical industry market forces that may impact our customers' success and continued demand for the products we produce for those customers; our ability to recruit or retain key scientific, technical, business development, and management personnel and our executive officers; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including current Good Manufacturing Practice, or cGMP; the outcome and cost of existing and any new litigation or regulatory proceedings; and other risk factors set forth from time to time in the company's filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, the Annual Report on Form 10-KT for the transition period ended December 31, 2025 (the "December 2025 10-KT"). For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the SEC, including the risk factors contained in the December 2025 10-KT. Forward-looking statements represent management's current expectations as of the date hereof and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.</p>  <p align="justify"><strong>Contact Information:<br></br></strong><strong>Vida Strategic Partners<br></br></strong>Stephanie Diaz (Investors)<br></br>415-675-7401<br></br><a href="https://www.globenewswire.com/Tracker?data=FA8RUAfQrmJnYjUx5y0D9HTcO8vsKfLMlBhiNqlMwxVBF-h1EfIETzAWlqyDF2at_1zSQ3wFs1UJCFjtSFXh6-j9cnb2VnjqmKv3LdD6nNE=" rel="nofollow" target="_blank">sdiaz@vidasp.com</a></p>  <p align="justify">Jennifer Arcure (Media)<br></br>917-603-0681<br></br><u><a href="https://www.globenewswire.com/Tracker?data=VGhNvLsuik3uFD0BAbTaRLlupxbol-j0QVtvKQb_Q2mTYnxZVeye3BDQ6qopWBTpvNvi5WJ8ybuNKuW56MyRl9u43MBLqeJv559DsJtS81Y=" rel="nofollow" target="_blank">jarcure@vidasp.com</a></u></p>  <p align="justify"><strong>Lifecore Biomedical<br></br></strong>Ryan D. Lake (CFO)<br></br>952-368-6244<br></br><a href="https://www.globenewswire.com/Tracker?data=nGvv_53xTC6CZytcvDOTq_BumX9tTwFupsDW1lnAIg_k1hR1k9wedD87Ru81WYox2Hj3z0WDdb5hQ7NlLCuTijLkf7uPB3Ha_sYm2cXlGb0=" rel="nofollow" target="_blank">ryan.lake@lifecore.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc0NjU0MSM3NjYwMDA4IzIwMDc3NTY="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ODExNTFjZmItZWM2NC00NDAwLTkwMDYtMjIzYmE4YzA5ODc4LTEwMTkzMjktMjAyNi0wNi0xNS1lbg==/tiny/Lifecore-Biomedical-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/ca940278-cc18-4a3f-93b7-d8a034c998c9"><img src="https://ml.globenewswire.com/media/ca940278-cc18-4a3f-93b7-d8a034c998c9/small/lifecore-corporate-logo-2c-png.png" border="0" width="150" height="63" alt="Primary Logo"></img></a></p>

Lifecore Biomedical announced a new tech transfer agreement with a global pharmaceutical company to support the commercial production of an injectable suspension for neurological disorders. This marks Lifecore's seventh late-stage program win in seven months, underscoring strong momentum and demand for high-viscosity, complex injectable manufacturing in the U.S. The development could improve revenue visibility and backlog while expanding Lifecore’s partner ecosystem.

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News